Top

Published in:

01-11-2015 | Review Article

Chemoradiotherapy and surgery for T4 esophageal cancer in Japan

Authors: Yasunori Akutsu, Hisahiro Matsubara

Published in: Surgery Today | Issue 11/2015

Abstract

Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness. The most effective treatment modality for esophageal cancer, particularly T4 esophageal cancer, is chemoradiotherapy (CRT). Some T4 patients show long-term survival after receiving CRT, suggesting that even T4 esophageal cancer can be cured with this modality. Although surgery is performed after CRT in some T4 cases, its prognostic benefit is controversial. In this paper, we review the status of CRT and conversion surgery as well as the development of new regimens and discuss the future prospects of CRT in the treatment of T4 esophageal cancer in Japan.

Shimada H, Shiratori T, Okazumi S, et al. Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg. 2008;206:48–56.CrossRefPubMed

Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive registry of esophageal cancer in Japan, 2006. Esophagus. 2013. doi:10.1007/s10388-013-0393-5.

Chak A, Canto M, Gerdes H, et al. Prognosis of esophageal cancers preoperatively staged to be locally invasive (T4) by endoscopic ultrasound (EUS): a multicenter retrospective cohort study. Gastrointest Endosc. 1995;42:501–6.CrossRefPubMed

Akutsu Y, Kono T, Uesato M, et al. Is the outcome of a salvage surgery for t4 thoracic esophageal squamous cell carcinoma really poor? World J Surg. 2014;38:2891–7CrossRefPubMed

Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–8.CrossRefPubMed

Pimiento JM, Weber J, Hoffe SE, et al. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013;20:2706–12.CrossRefPubMed

Seto Y, Chin K, Gomi K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007;98:937–42.CrossRefPubMed

Kuroda J, Yoshida M, Kitajima M, et al. Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma. J Gastroenterol Hepatol. 2012;27(Suppl 3):88–94.CrossRefPubMed

Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70:25–32.CrossRefPubMed

10.

Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–5.PubMedCentralCrossRefPubMed

11.

Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17:221–8.CrossRefPubMed

12.

Japan Esophageal Society. Guidelines for diagnosis and treatment of carcinoma of the esophagus. Tokyo: Kanehara; 2012.

13.

Ohtsu A, Yoshida S, Boku N, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 1995;25:261–6.PubMed

14.

Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed

15.

Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134–9.CrossRefPubMed

16.

Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.CrossRefPubMed

17.

Shinoda M, Ando N, Kato H, et al. A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). J Clin Oncol. 2010;28(No 15_suppl):Abstract 4053.

18.

Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.CrossRefPubMed

19.

Van Raemdonck D, Van Cutsem E, Menten J, Ectors N, Coosemans W, De Leyn P, Lerut T. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997;11:828–37.CrossRefPubMed

20.

Noguchi T, Moriyama H, Wada S, Takeno S, Wakisaka M, Mori H, Uchida Y. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus. 2003;16:94–8.CrossRefPubMed

21.

Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30 (discussion 30–1).CrossRefPubMed

22.

Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.CrossRefPubMed

23.

Fujita H, Sueyoshi S, Tanaka T, et al. Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol. 2005;90:209–19.CrossRefPubMed

24.

Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.CrossRefPubMed

25.

Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009;29:403–21.CrossRefPubMed

26.

Karimata H, Shimoji H, Nishimaki T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg Today. 2014.

27.

Wayman J, Chakraverty S, Griffin SM, Doyle GJ, Keir MJ, Simpson W. Evaluation of local invasion by oesophageal carcinoma—a prospective study of prone computed tomography scanning. Postgrad Med J. 2001;77:181–4.PubMedCentralCrossRefPubMed

28.

Ito B, Niwa Y, Ando N, et al. Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography. Eur J Radiol. 2005;54:377–82.CrossRefPubMed

29.

Yamada I, Izumi Y, Kawano T, Yoshino N, Tetsumura A, Kumagai J, Shibuya H. Esophageal carcinoma: evaluation with high-resolution three-dimensional constructive interference in steady state MR imaging in vitro. J Magn Reson Imaging. 2006;24:1326–32.CrossRefPubMed

30.

Wakamatsu T, Tsushima K, Yasuo M, et al. Usefulness of preoperative endobronchial ultrasound for airway invasion around the trachea: esophageal cancer and thyroid cancer. Respiration. 2006;73:651–7.CrossRefPubMed

31.

Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.CrossRefPubMed

32.

Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.CrossRefPubMed

33.

Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535–41.PubMed

34.

Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105:1189–95.PubMedCentralCrossRefPubMed

35.

Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106:441–7.CrossRefPubMed

36.

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease and oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.CrossRefPubMed

37.

Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014.

38.

Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18:2946–51.CrossRefPubMed

39.

Yusup G, Akutsu Y, Mutallip M, et al. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int J Oncol. 2014;44:1146–52.PubMed

40.

Yoneda M, Fujiwara H, Furutani A, et al. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. Anticancer Res. 2013;33:2699–705.PubMed

41.

Makuuchi Y, Honda K, Osaka Y, et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104:1045–51.CrossRefPubMed

42.

Zhang JX, Tong ZT, Yang L, et al. PITX2: a promising predictive biomarker of patients’ prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer. 2013;132:2567–77.CrossRefPubMed

43.

Imanishi S, Shuto K, Aoyagi T, Kono T, Saito H, Matsubara H. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg. 2013;30:240–8.CrossRefPubMed

44.

Akutsu Y, Yasuda S, Nagata M, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012;105:750–5.CrossRefPubMed

Title: Chemoradiotherapy and surgery for T4 esophageal cancer in Japan
Authors: Yasunori Akutsu
Hisahiro Matsubara
Publication date: 01-11-2015
Publisher: Springer Japan
Published in: Surgery Today / Issue 11/2015
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-015-1116-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Chemoradiotherapy and surgery for T4 esophageal cancer in Japan

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2015

Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons

A 10-year experience of totally extraperitoneal endoscopic repair for adult inguinal hernia

The modified Altemeier procedure for a loop colostomy prolapse

Recurrent intractable hiccups treated by cervical phrenic nerve block under electromyography: report of a case

A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn’s disease

Conversion of laparoscopic surgery for perforated peptic ulcer: a single-center study